Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights from 254,301 Patients from Randomized Trials

Mayo Clinic Proceedings

Volumn 91, Issue 1, 2016, Pages 51-60

  Bangalore, Sripal ^a   Fakheri, Robert ^a   Toklu, Bora ^b   Ogedegbe, Gbenga ^a   Weintraub, Howard ^a   Messerli, Franz H ^c,d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SENSITIVITY ANALYSIS; TREND STUDY; UNSPECIFIED SIDE EFFECT; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEART FUNCTION TEST; TREATMENT OUTCOME;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEART FUNCTION TESTS; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); TREATMENT OUTCOME;

EID: 84952802975     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2015.10.019     Document Type: Article

References (22)

1. K.M. Fox EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) Lancet 362 9386 2003 782 788
2. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, G. Dagenais The Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [published corrections appear in N Engl J Med. 2000;342(10):748 and 2000;342(18):1376] N Engl J Med 342 3 2000 145 153
3. S. Yusuf, H.C. Diener, R.L. Sacco, et al. PRoFESS Study Group Telmisartan to prevent recurrent stroke and cardiovascular events N Engl J Med 359 12 2008 1225 1237
4. H. Haller, S. Ito, J.L. Izzo Jr., et al. ROADMAP Trial Investigators Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes N Engl J Med 364 10 2011 907 917
5. M.M. Al Khalaf, L. Thalib, and S.A. Doi Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis Am J Cardiovasc Drugs 9 1 2009 29 43
6. Task Force Members, G. Montalescot, U. Sechtem, S. Achenbach, and et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology [published correction appears in Eur Heart J. 2014;35(33):2260-2261] Eur Heart J 34 38 2013 2949 3003
7. S.D. Fihn, J.C. Blankenship, K.P. Alexander, and et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation 130 19 2014 1749 1767
8. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: the Expert Panel Arch Intern Med 148 1 1988 36 69
9. S.M. Grundy, J.I. Cleeman, C.N. Merz, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [published correction appears in Circulation. 2004;110(6):763] Circulation 110 2 2004 227 239
10. Center for Disease Control and Prevention Crude and Age-Adjusted Percentage of People with Diabetes Aged 35 Years or Older Reporting Any Heart Disease or Stroke, United States, 1997-2011 2012 Center for Disease Control and Prevention Atlanta, GA
11. ONTARGET Investigators, S. Yusuf, K.K. Teo, J. Pogue, and et al. Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 15 2008 1547 1559
12. The Cochrane Collaboration J.P. Higgins, and S. Green Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.0 2008 Available at: www.cochrane-handbook.org Accessed December 12, 2013
13. D. Moher, D.J. Cook, S. Eastwood, I. Olkin, D. Rennie, and D.F. Stroup Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses Lancet 354 9193 1999 1896 1900
14. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 3 1986 177 188
15. R.F. Galbraith A note on graphical presentation of estimated odds ratios from several clinical trials Stat Med 7 8 1988 889 894
16. J.P. Higgins, and S.G. Thompson Controlling the risk of spurious findings from meta-regression Stat Med 23 11 2004 1663 1682
17. M.J. Bradburn, J.J. Deeks, and D.G. Altman sbe24: metan - an alternative meta-analysis command Stata Tech Bull 44 1998 15
18. L. Murphey, D. Vaughan, and N. Borwn Contribution of bradykinin to the cardioprotective effects of ACE inhibitors Eur Heart J Suppl 5 suppl A 2003 A37 A41
19. J. Cheng, W. Zhang, X. Zhang, and et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis JAMA Intern Med 174 5 2014 773 785
20. DREAM Trial Investigators, J. Bosch, S. Yusuf, H.C. Gerstein, and et al. Effect of ramipril on the incidence of diabetes N Engl J Med 355 15 2006 1551 1562
21. M.R. Law, J.K. Morris, and N.J. Wald Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies BMJ 338 2009 b1665
22. E.C. Li, B.S. Heran, and J.M. Wright Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension Cochrane Database Syst Rev 8 2014 CD009096